NO842168L - Terapeutisk anordning - Google Patents

Terapeutisk anordning

Info

Publication number: NO842168L
Authority: NO; Norway
Prior art keywords: body fluid; polymer; carrier; biospecific; polymeric carrier
Prior art date: 1983-06-01

Application number

NO842168A

Other languages

English (en)

Norwegian (no)

Inventor

Mark R Honard

Mark A Holmes

Robert D Jarrett

Original Assignee

Diamond Shamrock Chem

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-01

Filing date

1984-05-30

Publication date

1984-12-03

1984-05-30 Application filed by Diamond Shamrock Chem filed Critical Diamond Shamrock Chem

1984-12-03 Publication of NO842168L publication Critical patent/NO842168L/no

Links

230000001225 therapeutic effect Effects 0.000 title description 13
229920000642 polymer Polymers 0.000 claims description 91
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
201000010099 disease Diseases 0.000 claims description 48
210000001124 body fluid Anatomy 0.000 claims description 46
239000010839 body fluid Substances 0.000 claims description 46
238000011282 treatment Methods 0.000 claims description 30
230000001575 pathological effect Effects 0.000 claims description 28
239000012636 effector Substances 0.000 claims description 25
125000006850 spacer group Chemical group 0.000 claims description 22
239000000427 antigen Substances 0.000 claims description 21
-1 hydroxyalkyl acrylates Chemical class 0.000 claims description 17
108091007433 antigens Proteins 0.000 claims description 16
102000036639 antigens Human genes 0.000 claims description 16
239000012620 biological material Substances 0.000 claims description 16
229920000249 biocompatible polymer Polymers 0.000 claims description 15
229920001519 homopolymer Polymers 0.000 claims description 12
229920001577 copolymer Polymers 0.000 claims description 10
VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 claims description 9
108060003951 Immunoglobulin Proteins 0.000 claims description 8
102000018358 immunoglobulin Human genes 0.000 claims description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
239000000178 monomer Substances 0.000 claims description 8
102000004169 proteins and genes Human genes 0.000 claims description 8
108090000623 proteins and genes Proteins 0.000 claims description 8
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 7
208000023275 Autoimmune disease Diseases 0.000 claims description 7
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 7
238000013461 design Methods 0.000 claims description 7
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
239000000969 carrier Substances 0.000 claims description 6
239000006260 foam Substances 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
229940125396 insulin Drugs 0.000 claims description 5
201000009030 Carcinoma Diseases 0.000 claims description 4
239000004743 Polypropylene Substances 0.000 claims description 4
210000002469 basement membrane Anatomy 0.000 claims description 4
229920001155 polypropylene Polymers 0.000 claims description 4
108010009685 Cholinergic Receptors Proteins 0.000 claims description 3
102000004877 Insulin Human genes 0.000 claims description 3
108090001061 Insulin Proteins 0.000 claims description 3
239000004793 Polystyrene Substances 0.000 claims description 3
102000034337 acetylcholine receptors Human genes 0.000 claims description 3
108010074605 gamma-Globulins Proteins 0.000 claims description 3
239000000017 hydrogel Substances 0.000 claims description 3
229920000515 polycarbonate Polymers 0.000 claims description 3
239000004417 polycarbonate Substances 0.000 claims description 3
229920001296 polysiloxane Polymers 0.000 claims description 3
229920002223 polystyrene Polymers 0.000 claims description 3
102000005962 receptors Human genes 0.000 claims description 3
108020003175 receptors Proteins 0.000 claims description 3
229920001897 terpolymer Polymers 0.000 claims description 3
JJRUAPNVLBABCN-UHFFFAOYSA-N 2-(ethenoxymethyl)oxirane Chemical class C=COCC1CO1 JJRUAPNVLBABCN-UHFFFAOYSA-N 0.000 claims description 2
229920000742 Cotton Polymers 0.000 claims description 2
206010022489 Insulin Resistance Diseases 0.000 claims description 2
108010052285 Membrane Proteins Proteins 0.000 claims description 2
108010045503 Myeloma Proteins Proteins 0.000 claims description 2
102000005717 Myeloma Proteins Human genes 0.000 claims description 2
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical class CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 2
230000032823 cell division Effects 0.000 claims description 2
229920002301 cellulose acetate Polymers 0.000 claims description 2
102000006834 complement receptors Human genes 0.000 claims description 2
108010047295 complement receptors Proteins 0.000 claims description 2
210000002808 connective tissue Anatomy 0.000 claims description 2
239000004744 fabric Substances 0.000 claims description 2
239000000835 fiber Substances 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
229920000728 polyester Polymers 0.000 claims description 2
229920002477 rna polymer Polymers 0.000 claims description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
229940088594 vitamin Drugs 0.000 claims description 2
239000011782 vitamin Substances 0.000 claims description 2
229930003231 vitamin Natural products 0.000 claims description 2
235000013343 vitamin Nutrition 0.000 claims description 2
150000003926 acrylamides Chemical class 0.000 claims 2
239000004721 Polyphenylene oxide Substances 0.000 claims 1
UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical class NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 claims 1
RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 claims 1
229920006380 polyphenylene oxide Polymers 0.000 claims 1
239000000126 substance Substances 0.000 description 66
238000000034 method Methods 0.000 description 45
210000004369 blood Anatomy 0.000 description 32
239000008280 blood Substances 0.000 description 32
210000002381 plasma Anatomy 0.000 description 23
239000012530 fluid Substances 0.000 description 20
239000000463 material Substances 0.000 description 15
239000000243 solution Substances 0.000 description 15
239000000306 component Substances 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
239000007788 liquid Substances 0.000 description 10
238000000926 separation method Methods 0.000 description 9
239000003146 anticoagulant agent Substances 0.000 description 8
229940127219 anticoagulant drug Drugs 0.000 description 8
230000001363 autoimmune Effects 0.000 description 8
125000000524 functional group Chemical group 0.000 description 8
230000027455 binding Effects 0.000 description 7
238000009739 binding Methods 0.000 description 7
229920002678 cellulose Polymers 0.000 description 7
239000001913 cellulose Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
239000004593 Epoxy Substances 0.000 description 6
230000004913 activation Effects 0.000 description 6
239000012503 blood component Substances 0.000 description 6
239000000470 constituent Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000000758 substrate Substances 0.000 description 6
230000008901 benefit Effects 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
230000006870 function Effects 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
239000012528 membrane Substances 0.000 description 5
230000001613 neoplastic effect Effects 0.000 description 5
229920000307 polymer substrate Polymers 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
206010018364 Glomerulonephritis Diseases 0.000 description 4
206010025323 Lymphomas Diseases 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 4
229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 4
239000004676 acrylonitrile butadiene styrene Substances 0.000 description 4
150000001718 carbodiimides Chemical class 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
229940072221 immunoglobulins Drugs 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000011285 therapeutic regimen Methods 0.000 description 4
IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
241000233866 Fungi Species 0.000 description 3
208000035895 Guillain-Barré syndrome Diseases 0.000 description 3
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
239000011324 bead Substances 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
239000012876 carrier material Substances 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
201000001981 dermatomyositis Diseases 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
206010028417 myasthenia gravis Diseases 0.000 description 3
201000006292 polyarteritis nodosa Diseases 0.000 description 3
230000008569 process Effects 0.000 description 3
150000003180 prostaglandins Chemical class 0.000 description 3
230000004044 response Effects 0.000 description 3
230000002792 vascular Effects 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
238000005406 washing Methods 0.000 description 3
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 2
208000026872 Addison Disease Diseases 0.000 description 2
206010060935 Alloimmunisation Diseases 0.000 description 2
VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000023328 Basedow disease Diseases 0.000 description 2
208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
206010008909 Chronic Hepatitis Diseases 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
206010016717 Fistula Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
208000024869 Goodpasture syndrome Diseases 0.000 description 2
208000015023 Graves' disease Diseases 0.000 description 2
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
208000010159 IgA glomerulonephritis Diseases 0.000 description 2
206010021263 IgA nephropathy Diseases 0.000 description 2
208000024781 Immune Complex disease Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
206010049567 Miller Fisher syndrome Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000031845 Pernicious anaemia Diseases 0.000 description 2
208000012654 Primary biliary cholangitis Diseases 0.000 description 2
208000003782 Raynaud disease Diseases 0.000 description 2
208000012322 Raynaud phenomenon Diseases 0.000 description 2
229920001247 Reticulated foam Polymers 0.000 description 2
206010039710 Scleroderma Diseases 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
206010042276 Subacute endocarditis Diseases 0.000 description 2
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
102000009843 Thyroglobulin Human genes 0.000 description 2
108010034949 Thyroglobulin Proteins 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
210000004100 adrenal gland Anatomy 0.000 description 2
125000003172 aldehyde group Chemical group 0.000 description 2
XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000002429 anti-coagulating effect Effects 0.000 description 2
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
229960000074 biopharmaceutical Drugs 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
238000005266 casting Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
201000003278 cryoglobulinemia Diseases 0.000 description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000003618 dip coating Methods 0.000 description 2
206010014599 encephalitis Diseases 0.000 description 2
208000030172 endocrine system disease Diseases 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
208000028104 epidemic louse-borne typhus Diseases 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
208000001031 fetal erythroblastosis Diseases 0.000 description 2
230000003890 fistula Effects 0.000 description 2
125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 2
230000012010 growth Effects 0.000 description 2
208000014951 hematologic disease Diseases 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000007170 pathology Effects 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920005597 polymer membrane Polymers 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000005086 pumping Methods 0.000 description 2
239000000376 reactant Substances 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
238000007789 sealing Methods 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
230000001629 suppression Effects 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229960002175 thyroglobulin Drugs 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
206010061393 typhus Diseases 0.000 description 2
WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
SAHQQCUQWHJOCV-SNAWJCMRSA-N (e)-2-ethenylbut-2-enoic acid Chemical compound C\C=C(/C=C)C(O)=O SAHQQCUQWHJOCV-SNAWJCMRSA-N 0.000 description 1
FPIGOBKNDYAZTP-UHFFFAOYSA-N 1,2-epoxy-3-(4-nitrophenoxy)propane Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCC1OC1 FPIGOBKNDYAZTP-UHFFFAOYSA-N 0.000 description 1
VAYTZRYEBVHVLE-UHFFFAOYSA-N 1,3-dioxol-2-one Chemical compound O=C1OC=CO1 VAYTZRYEBVHVLE-UHFFFAOYSA-N 0.000 description 1
PXGZQGDTEZPERC-UHFFFAOYSA-N 1,4-cyclohexanedicarboxylic acid Chemical compound OC(=O)C1CCC(C(O)=O)CC1 PXGZQGDTEZPERC-UHFFFAOYSA-N 0.000 description 1
SGNXVBOIDPPRJJ-PSASIEDQSA-N 1-[(1r,6r)-9-azabicyclo[4.2.1]non-4-en-5-yl]ethanone Chemical compound CC(=O)C1=CCC[C@@H]2CC[C@H]1N2 SGNXVBOIDPPRJJ-PSASIEDQSA-N 0.000 description 1
VOCDJQSAMZARGX-UHFFFAOYSA-N 1-ethenylpyrrolidine-2,5-dione Chemical compound C=CN1C(=O)CCC1=O VOCDJQSAMZARGX-UHFFFAOYSA-N 0.000 description 1
HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
IEVADDDOVGMCSI-UHFFFAOYSA-N 2-hydroxybutyl 2-methylprop-2-enoate Chemical compound CCC(O)COC(=O)C(C)=C IEVADDDOVGMCSI-UHFFFAOYSA-N 0.000 description 1
OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
UWRZIZXBOLBCON-UHFFFAOYSA-N 2-phenylethenamine Chemical class NC=CC1=CC=CC=C1 UWRZIZXBOLBCON-UHFFFAOYSA-N 0.000 description 1
KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 1
SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
206010001324 Adrenal atrophy Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
206010004659 Biliary cirrhosis Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
108010091326 Cryoglobulins Proteins 0.000 description 1
208000014311 Cushing syndrome Diseases 0.000 description 1
206010011686 Cutaneous vasculitis Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108091023046 Deoxyribonucleoprotein Proteins 0.000 description 1
206010012455 Dermatitis exfoliative Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
208000003870 Drug Overdose Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
229940124135 Factor VIII inhibitor Drugs 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
206010051645 Idiopathic neutropenia Diseases 0.000 description 1
208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
208000004554 Leishmaniasis Diseases 0.000 description 1
206010024227 Lepromatous leprosy Diseases 0.000 description 1
208000022435 Light chain deposition disease Diseases 0.000 description 1
208000020647 Light chain disease Diseases 0.000 description 1
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
206010058858 Meningococcal bacteraemia Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
102000019040 Nuclear Antigens Human genes 0.000 description 1
108010051791 Nuclear Antigens Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000002774 Paraproteinemias Diseases 0.000 description 1
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
206010034277 Pemphigoid Diseases 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
206010035501 Plasmodium malariae infection Diseases 0.000 description 1
201000006537 Plasmodium malariae malaria Diseases 0.000 description 1
206010054047 Pneumococcal sepsis Diseases 0.000 description 1
208000005374 Poisoning Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
206010037151 Psittacosis Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010037779 Radiculopathy Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
201000000860 Secondary syphilis Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010058028 Shunt infection Diseases 0.000 description 1
241000589970 Spirochaetales Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
206010061372 Streptococcal infection Diseases 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
206010043780 Thyroiditis acute Diseases 0.000 description 1
206010043784 Thyroiditis subacute Diseases 0.000 description 1
208000007712 Tinea Versicolor Diseases 0.000 description 1
206010056131 Tinea versicolour Diseases 0.000 description 1
208000003441 Transfusion reaction Diseases 0.000 description 1
206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
208000037386 Typhoid Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
208000013633 acquired hemophilia Diseases 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
231100000354 acute hepatitis Toxicity 0.000 description 1
201000006498 acute thyroiditis Diseases 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
150000001299 aldehydes Chemical group 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
239000013566 allergen Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
239000003948 anatoxin Substances 0.000 description 1
230000002391 anti-complement effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
108010008730 anticomplement Proteins 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
210000002302 brachial artery Anatomy 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
PVEOYINWKBTPIZ-UHFFFAOYSA-N but-3-enoic acid Chemical compound OC(=O)CC=C PVEOYINWKBTPIZ-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000004568 cement Substances 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
229940107161 cholesterol Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
108010009717 circulating anticoagulants Proteins 0.000 description 1
230000004087 circulation Effects 0.000 description 1
210000003109 clavicle Anatomy 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000007334 copolymerization reaction Methods 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003210 demyelinating effect Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
125000005442 diisocyanate group Chemical group 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
231100000725 drug overdose Toxicity 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
208000004526 exfoliative dermatitis Diseases 0.000 description 1
201000001386 familial hypercholesterolemia Diseases 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000000585 glomerular basement membrane Anatomy 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
208000007386 hepatic encephalopathy Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
KIWQWJKWBHZMDT-UHFFFAOYSA-N homocysteine thiolactone Chemical compound NC1CCSC1=O KIWQWJKWBHZMDT-UHFFFAOYSA-N 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
201000001371 inclusion conjunctivitis Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
201000006747 infectious mononucleosis Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
229940029329 intrinsic factor Drugs 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000004807 localization Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
208000022089 meningococcemia Diseases 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
208000011771 monoclonal paraproteinemia disease Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
RQAKESSLMFZVMC-UHFFFAOYSA-N n-ethenylacetamide Chemical compound CC(=O)NC=C RQAKESSLMFZVMC-UHFFFAOYSA-N 0.000 description 1
KKFHAJHLJHVUDM-UHFFFAOYSA-N n-vinylcarbazole Chemical compound C1=CC=C2N(C=C)C3=CC=CC=C3C2=C1 KKFHAJHLJHVUDM-UHFFFAOYSA-N 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000001453 nonthrombogenic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
201000000901 ornithosis Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000003544 oxime group Chemical group 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
208000021090 palsy Diseases 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000003058 plasma substitute Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000012704 polymeric precursor Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920013637 polyphenylene oxide polymer Polymers 0.000 description 1
208000006473 polyradiculopathy Diseases 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000047 product Substances 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000001107 psychogenic effect Effects 0.000 description 1
210000002321 radial artery Anatomy 0.000 description 1
201000008158 rapidly progressive glomerulonephritis Diseases 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
239000000565 sealant Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000004528 spin coating Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
201000007497 subacute thyroiditis Diseases 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
208000005057 thyrotoxicosis Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
206010044325 trachoma Diseases 0.000 description 1
230000007704 transition Effects 0.000 description 1
ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
201000002311 trypanosomiasis Diseases 0.000 description 1
201000008297 typhoid fever Diseases 0.000 description 1
230000004222 uncontrolled growth Effects 0.000 description 1
239000002441 uremic toxin Substances 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/12—Flow characteristics the flow being spirally in a plane, e.g. against a plane side of a membrane filter element

Landscapes

Health & Medical Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Veterinary Medicine (AREA)
External Artificial Organs (AREA)
Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
Eye Examination Apparatus (AREA)
Surgical Instruments (AREA)
Manipulator (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Catching Or Destruction (AREA)
Photographic Processing Devices Using Wet Methods (AREA)
Materials For Medical Uses (AREA)

NO842168A 1983-06-01 1984-05-30 Terapeutisk anordning NO842168L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US49998983A	1983-06-01	1983-06-01

Publications (1)

Publication Number	Publication Date
NO842168L true NO842168L (no)	1984-12-03

Family

ID=23987585

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO842168A NO842168L (no)	1983-06-01	1984-05-30	Terapeutisk anordning

Country Status (17)

Country	Link
EP (1)	EP0132534B1 (pt)
JP (1)	JPS605167A (pt)
KR (1)	KR910004329B1 (pt)
AT (1)	ATE65413T1 (pt)
AU (2)	AU2883384A (pt)
BR (1)	BR8402614A (pt)
CA (1)	CA1236738A (pt)
DD (1)	DD220500A5 (pt)
DE (1)	DE3484831D1 (pt)
DK (1)	DK267884A (pt)
IL (1)	IL71983A (pt)
IN (1)	IN160675B (pt)
MX (1)	MX155537A (pt)
NO (1)	NO842168L (pt)
PL (1)	PL247978A1 (pt)
YU (1)	YU93184A (pt)
ZA (1)	ZA844121B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5061237A (en) *	1985-07-02	1991-10-29	Cytomed Medizintechnik Gmbh	Method of purifying whole blood
DE3523616A1 (de) *	1985-07-02	1987-01-15	Cytomed Medizintechnik	Filter
DE3671376D1 (de) *	1985-07-02	1990-06-28	Cytomed Medizintechnik	Medizinisches geraet, insbesondere filter, kanuele, katheter oder implantat.
ES2188580T3 (es) *	1989-08-02	2003-07-01	Mitra Medical Technology Ab	Sistema para uso en un metodo de tratamiento terapeutico o de diagnostico.
SE9100142L (sv)	1991-01-17	1992-07-18	Bengt Sandberg	En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
DE4113602A1 (de) *	1991-04-23	1992-10-29	Falkenhagen Dieter Dr Sc Med	Endotoxinadsorber und verfahren zu seiner herstellung
US5972102A (en) *	1996-10-29	1999-10-26	North American Refractories Co.	Hydraulically-bonded monolithic refractories containing a calcium oxide-free binder comprised of a hydratable alumina source and magnesium oxide
RU2178313C1 (ru) *	2000-08-29	2002-01-20	Кутушов Михаил Владимирович	Композиция для экстракорпоральной обработки биологических жидкостей и способ получения магнитоуправляемого сорбента для ее осуществления (варианты)
GB0112363D0 (en) *	2001-05-21	2001-07-11	Allied Therapeutics Ltd	Method and apparatus for treating biological fluids
US10905818B2 (en) *	2014-03-31	2021-02-02	Zoll Medical Corporation	Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome
CA3013636A1 (en) *	2016-03-08	2017-09-14	Cytosorbents Corporation	The use of a hemocompatible porous polymer bead sorbent for removal of pamps and damps
JP2022548026A (ja) *	2019-09-13	2022-11-16	ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー	血液中のａｄｍａを調節するデバイスおよび方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3794584A (en) *	1970-04-09	1974-02-26	Rohm & Haas	Removal of poisons and drugs from blood
SE383258B (sv) *	1970-12-11	1976-03-08	V H Hyden	Anordning for att i terapeutiskt syfte selektivt och under kontroll avskilja icke onskade bestandsdelar ur blod
CS167530B1 (en) *	1972-03-29	1976-04-29	Jiri Coupek	Method of insoluble biologically active compounds preparation
US3826678A (en) *	1972-06-06	1974-07-30	Atomic Energy Commission	Method for preparation of biocompatible and biofunctional materials and product thereof
US3896217A (en) *	1973-03-19	1975-07-22	Summa Corp	Method and apparatus for radioimmunoassay with regeneration of immunoadsorbent
JPS56145858A (en) *	1980-04-15	1981-11-12	Unitika Ltd	Purifier for body fluid
JPS5743744A (en) *	1980-08-26	1982-03-11	Toyo Boseki	Peculiar adsorber
CA1177751A (en) *	1980-12-09	1984-11-13	Shuntaro Hosaka	Immunoparticles and process for preparing same
US4381004A (en) *	1981-01-15	1983-04-26	Biomedics, Inc.	Extracorporeal system for treatment of infectious and parasitic diseases
DE3109123A1 (de) *	1981-03-11	1982-09-23	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München	Verfahren zur kovalenten immobilisierung von biologischen detoxikationssystemen auf kuenstlichen oberflaechen
US4430229A (en) *	1981-05-22	1984-02-07	Asahi Kasei Kogyo Kabushiki Kaisha	Immune adsorbent and adsorbing device
JPS58173553A (ja) *	1982-04-01	1983-10-12	旭化成株式会社	血漿浄化装置
JPS5922557A (ja) *	1982-07-30	1984-02-04	旭化成株式会社	エンドトキシン血症治療器
JPS59168858A (ja) *	1983-03-17	1984-09-22	旭化成株式会社	糖含有物質の吸着浄化器

1984
- 1984-05-09 CA CA000453903A patent/CA1236738A/en not_active Expired
- 1984-05-25 AT AT84105986T patent/ATE65413T1/de not_active IP Right Cessation
- 1984-05-25 EP EP84105986A patent/EP0132534B1/en not_active Expired - Lifetime
- 1984-05-25 DE DE8484105986T patent/DE3484831D1/de not_active Expired - Fee Related
- 1984-05-30 DK DK267884A patent/DK267884A/da not_active Application Discontinuation
- 1984-05-30 AU AU28833/84A patent/AU2883384A/en not_active Abandoned
- 1984-05-30 ZA ZA844121A patent/ZA844121B/xx unknown
- 1984-05-30 IN IN398/MAS/84A patent/IN160675B/en unknown
- 1984-05-30 NO NO842168A patent/NO842168L/no unknown
- 1984-05-30 BR BR8402614A patent/BR8402614A/pt unknown
- 1984-05-31 JP JP59112178A patent/JPS605167A/ja active Granted
- 1984-05-31 YU YU00931/84A patent/YU93184A/xx unknown
- 1984-05-31 PL PL24797884A patent/PL247978A1/xx unknown
- 1984-05-31 DD DD84263650A patent/DD220500A5/de not_active IP Right Cessation
- 1984-05-31 IL IL71983A patent/IL71983A/xx unknown
- 1984-05-31 KR KR1019840003016A patent/KR910004329B1/ko not_active Expired
- 1984-05-31 MX MX201511A patent/MX155537A/es unknown
1988
- 1988-10-10 AU AU23586/88A patent/AU610258B2/en not_active Ceased

Also Published As

Publication number	Publication date
IL71983A0 (en)	1984-09-30
KR910004329B1 (ko)	1991-06-26
IL71983A (en)	1989-08-15
KR850000960A (ko)	1985-03-14
PL247978A1 (en)	1985-04-24
EP0132534B1 (en)	1991-07-24
JPS605167A (ja)	1985-01-11
AU610258B2 (en)	1991-05-16
IN160675B (pt)	1987-07-25
AU2358688A (en)	1989-01-12
CA1236738A (en)	1988-05-17
DK267884D0 (da)	1984-05-30
EP0132534A2 (en)	1985-02-13
DK267884A (da)	1984-12-02
ATE65413T1 (de)	1991-08-15
JPH0526508B2 (pt)	1993-04-16
AU2883384A (en)	1984-12-06
EP0132534A3 (en)	1985-12-18
DD220500A5 (de)	1985-04-03
BR8402614A (pt)	1985-04-30
MX155537A (es)	1988-03-24
YU93184A (en)	1988-02-29
ZA844121B (en)	1984-12-24
DE3484831D1 (de)	1991-08-29

Publication	Publication Date	Title
US4685900A (en)	1987-08-11	Therapeutic device
US4687808A (en)	1987-08-18	Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors
US4737544A (en)	1988-04-12	Biospecific polymers
US5871649A (en)	1999-02-16	Affinity membrane system and method of using same
Sanchez et al.	2013	The selective therapeutic apheresis procedures
NO842168L (no)	1984-12-03	Terapeutisk anordning
EP0103184B1 (en)	1990-01-17	Activation of biocompatible terpolymers with biologicals whose binding complements are pathological effectors
JP2649224B2 (ja)	1997-09-03	体液処理装置の滅菌方法および滅菌された体液処理装置
NO160968B (no)	1989-03-13	Bioforenlige polymerer med biologiske komponenter hvis bindingskomplementer er patologiske fremkallere.
JPH0135670B2 (pt)	1989-07-26
Vallar et al.	1996	Regenerated cellulose‐based hemodialyzers with immobilized proteins as potential devices for extracorporeal immunoadsorption procedures: an assessment of protein coupling capacity and in vitro dialysis performances
Samtleben et al.	1987	Ex vivo and in vivo protein A perfusion: background, basic investigations, and first clinical experiences
CA1217424A (en)	1987-02-03	Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors
JPS5810055A (ja)	1983-01-20	免疫吸着器の製造方法
Blomberg et al.	1993	Improved removal of anti-A and anti-B antibodies from plasma using blood-group-active haptens
JPS5854959A (ja)	1983-04-01	免疫吸着装置の製造方法
JP2726662B2 (ja)	1998-03-11	吸着体およびそれを用いた除去装置
JPH0347104B2 (pt)	1991-07-18
JPS639450A (ja)	1988-01-16	体液成分分離材およびこれを備えた体液成分分離装置
JPH0771632B2 (ja)	1995-08-02	吸着体およびそれを用いた除去装置
JPS60126165A (ja)	1985-07-05	血液適合性吸着材
JPH0215222B2 (pt)	1990-04-11
Cepparrone et al.	1993	Therapeutic Plasma Adsorption. A Review
JPS61206457A (ja)	1986-09-12	悪性物質の吸着材と吸着装置
JPS58173553A (ja)	1983-10-12	血漿浄化装置